Clinical remission among severe asthmatics on monoclonal antibody therapy: real-world outcomes at 2 years

Clinical remission among severe asthmatics on monoclonal antibody therapy: real-world outcomes at 2 years

Real-world data suggest clinical remission is a feasible treatment goal of monoclonal antibody therapy. Evidence of ongoing response post-12 months may be used to inform treatment decisions. Further work is needed to standardise criteria for remission. https://bit.ly/4cA6TkG.Real-world data suggest...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:ERJ open research 2024-11, Vol.10 (6), p.261
Hauptverfasser: Fyles, Fred, Burton, Rachel, Nuttall, Amy, Joplin, Hannah, Watkins, Laura, Burhan, Hassan
Format: Artikel
Sprache:eng
Schlagworte:
Research Letters
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Real-world data suggest clinical remission is a feasible treatment goal of monoclonal antibody therapy. Evidence of ongoing response post-12 months may be used to inform treatment decisions. Further work is needed to standardise criteria for remission. https://bit.ly/4cA6TkG.Real-world data suggest clinical remission is a feasible treatment goal of monoclonal antibody therapy. Evidence of ongoing response post-12 months may be used to inform treatment decisions. Further work is needed to standardise criteria for remission. https://bit.ly/4cA6TkG.
ISSN:2312-0541
2312-0541
DOI:10.1183/23120541.00261-2024